中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
20期
9226-9230
,共5页
预处理化疗%细胞因子诱导的杀伤细胞%免疫调节%髓源性抑制细胞
預處理化療%細胞因子誘導的殺傷細胞%免疫調節%髓源性抑製細胞
예처이화료%세포인자유도적살상세포%면역조절%수원성억제세포
Preconditioning chemotherapy%CIK cells%Immunomodulation%Myeloid-derived suppressor cells
目的:通过观察不同剂量的顺铂(Cisplatin,DDP)对B16黑色素瘤荷瘤鼠髓源性抑制细胞(myeloid-derived suppressor cells,MDSCs)的下调作用,探讨介导DDP免疫调节作用的机制。方法建立C57BL/6鼠B16黑色素瘤模型,随机分为三组:生理盐水(normal saline,NS)组:予NS;DDP 2.5 mg/kg组:予DDP 2.5 mg/kg,ip;DDP 5 mg/kg组:予DDP 5 mg/kg,ip。流式细胞术检测DDP处理后荷瘤鼠肿瘤组织、外周血中MDSCs、CD3+T细胞及自然杀伤(natural killer,NK)细胞比例的变化。绘制肿瘤生长曲线比较不同剂量的DDP对细胞因子诱导的杀伤细胞(cytokine-induced killer cells,CIK cells)抑瘤作用的增效作用。结果 DDP可显著降低肿瘤组织中MDSCs的比例(P<0.05),而对外周血中CD3+T细胞及NK细胞的比例无显著作用;两种剂量的DDP(2.5 mg/kg vs.5 mg/kg)对MDSCs的下调作用无显著差异。DDP预处理可显著增强CIK细胞对B16黑色素瘤的抑制作用(P<0.05);此种增效作用在DDP的两种剂量组(2.5 mg/kg vs.5 mg/kg)间无统计学差异。结论在B16黑色素瘤模型中,DDP预处理可增强CIK细胞免疫治疗的疗效,且此种增效作用与DDP选择性下调肿瘤组织中MDSCs的比例相关。
目的:通過觀察不同劑量的順鉑(Cisplatin,DDP)對B16黑色素瘤荷瘤鼠髓源性抑製細胞(myeloid-derived suppressor cells,MDSCs)的下調作用,探討介導DDP免疫調節作用的機製。方法建立C57BL/6鼠B16黑色素瘤模型,隨機分為三組:生理鹽水(normal saline,NS)組:予NS;DDP 2.5 mg/kg組:予DDP 2.5 mg/kg,ip;DDP 5 mg/kg組:予DDP 5 mg/kg,ip。流式細胞術檢測DDP處理後荷瘤鼠腫瘤組織、外週血中MDSCs、CD3+T細胞及自然殺傷(natural killer,NK)細胞比例的變化。繪製腫瘤生長麯線比較不同劑量的DDP對細胞因子誘導的殺傷細胞(cytokine-induced killer cells,CIK cells)抑瘤作用的增效作用。結果 DDP可顯著降低腫瘤組織中MDSCs的比例(P<0.05),而對外週血中CD3+T細胞及NK細胞的比例無顯著作用;兩種劑量的DDP(2.5 mg/kg vs.5 mg/kg)對MDSCs的下調作用無顯著差異。DDP預處理可顯著增彊CIK細胞對B16黑色素瘤的抑製作用(P<0.05);此種增效作用在DDP的兩種劑量組(2.5 mg/kg vs.5 mg/kg)間無統計學差異。結論在B16黑色素瘤模型中,DDP預處理可增彊CIK細胞免疫治療的療效,且此種增效作用與DDP選擇性下調腫瘤組織中MDSCs的比例相關。
목적:통과관찰불동제량적순박(Cisplatin,DDP)대B16흑색소류하류서수원성억제세포(myeloid-derived suppressor cells,MDSCs)적하조작용,탐토개도DDP면역조절작용적궤제。방법건립C57BL/6서B16흑색소류모형,수궤분위삼조:생리염수(normal saline,NS)조:여NS;DDP 2.5 mg/kg조:여DDP 2.5 mg/kg,ip;DDP 5 mg/kg조:여DDP 5 mg/kg,ip。류식세포술검측DDP처리후하류서종류조직、외주혈중MDSCs、CD3+T세포급자연살상(natural killer,NK)세포비례적변화。회제종류생장곡선비교불동제량적DDP대세포인자유도적살상세포(cytokine-induced killer cells,CIK cells)억류작용적증효작용。결과 DDP가현저강저종류조직중MDSCs적비례(P<0.05),이대외주혈중CD3+T세포급NK세포적비례무현저작용;량충제량적DDP(2.5 mg/kg vs.5 mg/kg)대MDSCs적하조작용무현저차이。DDP예처리가현저증강CIK세포대B16흑색소류적억제작용(P<0.05);차충증효작용재DDP적량충제량조(2.5 mg/kg vs.5 mg/kg)간무통계학차이。결론재B16흑색소류모형중,DDP예처리가증강CIK세포면역치료적료효,차차충증효작용여DDP선택성하조종류조직중MDSCs적비례상관。
Objective To observe the dynamic changes of myeloid-derived suppressor cells(MDSCs) after cisplatin (DDP) treatment in a murine B16 melanoma model and to elucidate the underlying mechanisms mediating the immuno-stimulating effect of DDP precondition. Methods C57BL/6 mice were injected with B16 cells to establish the murine melanoma model and then randomly divided into three groups. (a) Group Normal Saline (NS):administered with NS;(b) Group DDP 2.5 mg/kg:administered with DDP 2.5 mg/kg;(c) Group DDP 5 mg/kg: administered with DDP 5 mg/kg. The percentages of MDSCs and endogenous effector cells in tumor tissues and peripheral blood after DDP treatment were analyzed through flow cytometry. Tumor volumes were monitored to evaluate the efficacy-enhancing effect of DDP with different doses. Results In B16 melanoma model, DDP could significantly decrease the percentages of MDSCs in tumor tissues (P<0.05), whereas exerting no effect on the levels of CD3+ T lymphocytes and natural killer(NK) cells (P>0.05). There were no significances of MDSCs downregulation and efficacy-enhancing effect between the two doses of preconditioning DDP (P>0.05). Conclusion DDP precondition could selectively decrease the percentages of MDSCs in B16 melanoma model, which may contribute to the efficacy-enhancing effect of DDP.